Real-world management of immune-related adverse events in the community setting

被引：0
|
作者：
Johnson, D. B. [1 ]
Bruno, D. [2 ]
Rioth, M. [3 ]
Zhang, C. [4 ]
Palaia, J. [5 ]
Pisupati, R. [6 ]
Bond, C. [7 ]
Rosenblatt, L. C. [8 ]
Broome, R. G. [9 ]
Teka, M. [10 ]
Kluger, H. [11 ]
机构：
[1] Vanderbilt Univ, Hematol Oncol, Med Ctr, Nashville, TN USA
[2] Case Western Reserve Univ, Med, Univ Hosp, Cleveland, OH USA
[3] Syapse, Med Oncol, San Francisco, CA USA
[4] Syapse, Data Insights, San Francisco, CA USA
[5] BMS Bristol Myers Squibb, Hlth Econ & Outcomes Res, Princeton, NJ USA
[6] Bristol Myers Squibb, Princeton, NJ USA
[7] BMS Bristol Myers Squibb, Epidemiol, Princeton, NJ USA
[8] Bristol Myers Squibb, WW Hlth Econ & Outcomes Res US Market, Lawrenceville, GA USA
[9] Syapse, Clin Abstract, San Francisco, CA USA
[10] Syapse, Insights Analyt, San Francisco, CA USA
[11] Yale Canc Ctr, Oncol, Breast Ctr, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1675
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1582P
引用
收藏
页码：S1268 / S1269
页数：2
相关论文
共 50 条
  • [21] Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis
    Brown, Victoria T.
    Antol, Dana Drzayich
    Racsa, Patrick N.
    Ward, Melea A.
    Naidoo, Jarushka
    CANCER INVESTIGATION, 2021, 39 (10) : 789 - 796
  • [22] Comment on Ophthalmic Immune-Related Adverse Events and Association With Survival: Results From a Real-World Database
    Lum, Flora
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2025, 270 : 277 - 277
  • [23] Evaluating immune-related adverse events (irAEs) in a real-world cohort with lung cancer receiving immunotherapy
    Hu, Xiao
    Pan, Stacey
    Salei, Yana V.
    Lin, Jeffrey H.
    Parsons, Susan K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E32 - E32
  • [24] Incidence and management of severe immune-related adverse events in a regional Australian setting
    Davies, Amy
    Roscoe, Danielle
    Wright, Tricia
    Iddawela, Mahesh
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 170 - 170
  • [25] Immunotherapy - immune-related adverse events and their management
    Petrausch, Ulf
    THERAPEUTISCHE UMSCHAU, 2019, 76 (04) : 195 - 198
  • [26] Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors
    Hu, Xiao
    Rodday, Angie Mae
    Gurinovich, Anastasia
    Pan, Stacey
    Salei, Yana V.
    Lin, Jeffrey H.
    Byrne, Margaret M.
    Cao, Yu
    Pai, Lori
    Parsons, Susan K.
    IMMUNOTHERAPY, 2025,
  • [27] Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data
    Shimozaki, Keitaro
    Sukawa, Yasutaka
    Sato, Yasunori
    Horie, Sara
    Chida, Akihiko
    Tsugaru, Kai
    Togasaki, Kazuhiro
    Kawasaki, Kenta
    Hirata, Kenro
    Hayashi, Hideyuki
    Hamamoto, Yasuo
    Kanai, Takanori
    FUTURE ONCOLOGY, 2021, 17 (20) : 2593 - 2603
  • [28] Immune-related adverse events: The experience of a community hospital
    Baptista de Almeida, S.
    Honorio, M.
    Guerra, N.
    Fiuza, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 21 - 21
  • [29] Patterns and risk factors of immune-related adverse events in a real-world cohort with lung cancer receiving immunotherapy
    Hu, Xiao
    Gurinovich, Anastasia
    Pan, Stacey
    Salei, Yana
    Lin, Jeffrey
    Parsons, Susan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Real-World Characterization of Immune-Related Adverse Events in Nova Scotia Patients Treated with Pembrolizumab or Durvalumab and Adherence to Toxicity Management Guidelines
    Bowles, S.
    Daniels, A.
    DiCostanzo, T.
    Minard, L.
    Scott, S.
    Snow, S.
    Teimouri, A.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2024, 77 (02):
12345